In the latest trading session,, 0.51 million Carisma Therapeutics Inc (NASDAQ:CARM) shares changed hands as the company’s beta touched 1.54. With the company’s most recent per share price at $1.00 changed hands at -$0.01 or -0.50% at last look, the market valuation stands at $41.76M. CARM’s current price is a discount, trading about -422.0% off its 52-week high of $5.22. The share price had its 52-week low at $0.80, which suggests the last value was 20.0% up since then. When we look at Carisma Therapeutics Inc’s average trading volume, we note the 10-day average is 97510.0 shares, with the 3-month average coming to 799.77K.
Analysts gave the Carisma Therapeutics Inc (CARM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CARM as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Carisma Therapeutics Inc’s EPS for the current quarter is expected to be -0.28.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Carisma Therapeutics Inc (NASDAQ:CARM) trade information
Instantly CARM was in red as seen in intraday trades today. With action 0.50%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -65.70%, with the 5-day performance at 0.50% in the green. However, in the 30-day time frame, Carisma Therapeutics Inc (NASDAQ:CARM) is 13.52% up. Looking at the short shares, we see there were 1.12 million shares sold at short interest cover period of 4.25 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 83.33% from its recent market value. According to analyst projections, CARM’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -500.0% plunge from its current level, while the stock would need to soar -500.0% for it to hit the projected low.
Carisma Therapeutics Inc (CARM) estimates and forecasts
Data shows that the Carisma Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -58.30% over the past 6 months, a 44.79% in annual growth rate that is considerably higher than the industry average of 20.20%. Year-over-year growth is forecast to reach 51.00% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 4.97M. 3 analysts are of the opinion that Carisma Therapeutics Inc’s revenue for the current quarter will be 4.97M. The company’s revenue for the corresponding quarters a year ago was 3.83M and 4.29M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 29.90%. The estimates for the next quarter sales put growth at 15.90%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 24.98%. The 2024 estimates are for Carisma Therapeutics Inc earnings to increase by 52.83%.
Carisma Therapeutics Inc (NASDAQ:CARM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 28.68% of Carisma Therapeutics Inc shares while 33.82% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 47.42%.
